BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36530960)

  • 21. Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination.
    Gouda W; Albasri A; Alsaqabi F; Al Sabah HY; Alkandari M; Abdelnaby H
    J Korean Med Sci; 2022 Feb; 37(5):e32. PubMed ID: 35132838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
    Ikeda S; Arita M; Morita M; Ikeo S; Ito A; Tokioka F; Noyama M; Misaki K; Notohara K; Ishida T
    BMC Pulm Med; 2015 Dec; 15():159. PubMed ID: 26651481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Isono T; Nakajima H; Takano K; Kobayashi Y; Kawabata Y; Shimizu Y; Takayanagi N
    Respir Med Case Rep; 2021; 34():101491. PubMed ID: 34381685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review.
    Stewart JA; Price T; Moser S; Mullikin D; Bryan A
    Pediatr Rheumatol Online J; 2022 Feb; 20(1):16. PubMed ID: 35193600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series.
    Saito T; Mizobuchi M; Miwa Y; Sugiyama M; Mima Y; Iida A; Kanazawa N; Morikawa T; Hayashi J; Fukuda K; Shikida Y; Suzuki T; Honda H
    J Clin Apher; 2021 Feb; 36(1):196-205. PubMed ID: 32823371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis.
    Aissaoui H; Alsibai KD; Khayath N
    Clin Pract; 2021 Apr; 11(2):235-240. PubMed ID: 33922105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
    Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Japanese-American female with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Takada T; Asakawa K; Barrios R
    Clin Rheumatol; 2021 Mar; 40(3):1159-1165. PubMed ID: 32676922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case Report: Extracorporeal Membrane Oxgenation for Rapidly Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis in a Post-partum Woman.
    Gu Q; Diao M; Hu W; Huang M; Zhu Y
    Front Med (Lausanne); 2021; 8():742823. PubMed ID: 34660647
    [No Abstract]   [Full Text] [Related]  

  • 36. On the Nose: Anti-MDA-5 Dermatomyositis Manifesting as Perinasal Swelling.
    Molina E; Christopher-Stine L; Albayda J
    Case Rep Dermatol; 2022; 14(1):1-5. PubMed ID: 35221959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Report: Treatment of Anti-MDA5-Positive Amyopathic Dermatomyositis Accompanied by a Rapidly Progressive Interstitial Lung Diseases With Methylprednisolone Pulse Therapy Combined With Cyclosporine A and Hydroxychloroquine.
    Zhang QC; Liu MY; Chen ZX; Chen YT; Lin CS; Xu Q
    Front Med (Lausanne); 2020; 7():610554. PubMed ID: 33330573
    [No Abstract]   [Full Text] [Related]  

  • 38. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
    Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.